Quick Search


 

Result Summaries: dolutegravir/abacavir/lamivudine

ViiV
Study ID
   Phase    Title Summary (Download)
117172 phase 3 A Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine Once Daily Compared to Atazanavir and Ritonavir Plus Tenofovir/Emtricitabine Once Daily in HIV-1 Infected Antiretroviral Therapy Naïve Women (0 citation(s)) Click here to download result summary.
200402 Phase 1 A Phase I, single dose, five-period crossover relative bioavailability study of a fixed-dose combination dolutegravir/abacavir/lamivudine dispersible tablet as compared to a co-dose of TIVICAY and EPZICOM in healthy subjects (0 citation(s)) Click here to download result summary.
201147 phase 3 201147: a Phase IIIb, randomized, open-label study of the safety, efficacy, and tolerability of switching to a fixed-dose combination of abacavir/dolutegravir/ lamivudine from current antiretroviral regimen compared with continuation of the current antiretroviral regimen in HIV-1 infected adults who are virologically suppressed, The STRIIVING Study. (0 citation(s)) Click here to download result summary.
204662 Phase 1 A Phase I, Open-label, Single-dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of abacavir/dolutegravir/lamivudine fixed-dose combination tablets in Healthy Japanese Subjects (0 citation(s)) Click here to download result summary.
205824 Phase 4 A retrospective clinical audit of high case load General Practices in Australia with patients switched to Triumeq to determine the motivation for switch and clinical outcomes after the switch (0 citation(s)) Click here to download result summary.